LOS ANGELES — Shohei Ohtani is keeping elite company. The Japanese superstar caps 2024 by winning The Associated Press Male Athlete of the Year for the third time, tying him with basketball great Michael Jordan. He trails only four-time winners Lance Armstrong, Tiger Woods and LeBron James. "I'm very honored," Ohtani said through translator Matt Hidaka in an exclusive interview with the AP. "Obviously all the hard work has paid off. Maybe next year, I'll get the award again." In balloting by 74 sports journalists from the AP and its members, Ohtani received 48 votes. He previously won the award in 2023 and 2021, when he was with the Angels. "Growing up in Japan, I did follow Michael Jordan and Tiger Woods," he said. "I would see their accolades and how they were successful in the United States." The AP honor has been given out since 1931. Golfer Babe Didrikson won six times, the most by a man or woman. Swimmer Léon Marchand of France, who won four gold medals at the Paris Olympics, was second with 10 votes in balloting announced Monday. Golfer Scottie Scheffler, whose victories this year included the Masters and an Olympic gold medal, was third with nine. The AP Female Athlete of the Year will be announced Tuesday. Moving from the beleaguered Los Angeles Angels to the powerhouse Los Angeles Dodgers, Ohtani won his third Most Valuable Player award and first in the National League, led his new team to its eighth World Series championship and created Major League Baseball's 50/50 club by hitting 54 home runs and stealing 59 bases. Ohtani signed a then-record $700 million, 10-year contract with the Dodgers in December 2023. Already a two-way superstar, he embellished his reputation even further despite not pitching all season while he rehabilitated from a second major right elbow surgery he had in September 2023. Ohtani went wild on offense, making every at-bat a must-see moment. The 6-foot-4 designated hitter batted a career-high .310 while easily surpassing his previous career highs in home runs and stolen bases. In September, he reached the previously unheard of 50/50 mark in a performance for the ages. Against the Miami Marlins in Florida, Ohtani went 6 for 6 with three homers, 10 RBIs, two stolen bases and 17 total bases. "It wouldn't shock me if he went 60/60 and 20 wins a year from now," Brad Ausmus, who managed the Angels in 2019 during Ohtani's second season in Anaheim, said recently. "This guy is the greatest athlete to ever play the sport of baseball and there's not a close second." Ohtani said he knew the Dodgers' franchise record for most homers in a season was 49. His previous best was 46, set in 2021. "I kind of wanted to get over that bar," he said. "I was pleasantly surprised I was able to pass that record." Ohtani carried the Dodgers offensively during the regular season, and he stayed healthy until Game 2 of the World Series. He injured his left shoulder trying to steal second base against the New York Yankees and finished the Series playing hurt. He underwent surgery a few days after the Dodgers celebrated their championship in early November. "I don't have full range of motion yet, but it feels a lot better," he told the AP. "There's no pain. There's obviously still a little bit of tightness, but slowly but surely it's getting better." Ohtani recently received an updated rehab schedule, and he's focused on the near-term. "It's the small steps that I think are very important to get me to the ultimate goal, which is to just get back healthy," he said. Ohtani is also throwing in the 70 mph range, which is typical for pitchers early in the offseason. "I'm going to continue to ramp up slowly," he said. The Dodgers' rotation for next season is in flux, and Ohtani is waiting to see how it shakes out. "We may go with a five-man rotation with a bullpen (game), which is what we did a lot during this season or we may have a six-man rotation," he said. "But it's all about balancing out when we can get rest and recuperate. We'll see where that takes us along the playoff chase. I've got to obviously pace myself, but again that situation will guide us to how we get there." The Dodgers open the 2025 season in Japan, where Ohtani is even more closely watched. "My personal goal is to be fully healthy by the time the opening games do start," he said. "To be able to pitch and hit would be great, but the situation will kind of guide itself." Each time Ohtani comes to the plate or steps on the mound, there's great pressure and expectation for him to perform spectacular feats. "I just go out there and try to stay within myself," he said. "I can only control what I can control and that's where you trust your teammates. The guys behind me, you trust they're going to make the plays for you. I don't really try to overthink it." Ohtani generated big bucks for the Dodgers off the field, too. Fans traveled from Japan in droves to see him play around the U.S. At Dodger Stadium, they paid extra for tours of baseball's third-oldest venue narrated by Japanese-speaking guides and to be on the field during pre-game batting practice. A majority of the fans bought Ohtani-branded merchandise, especially his No. 17 jersey. Ohtani's presence also helped the Dodgers land a bevy of new Japanese sponsors. Because Ohtani prefers to speak Japanese and use an interpreter with the media, he is shrouded in a bit of mystique. Asked before his first postgame series if he was nervous, he dropped a one-word answer in English: "Nope," which drew laughter. Japanese-born Dodgers manager Dave Roberts observed Ohtani's behind-the-scenes interactions with his teammates, coaches and staff, and came away impressed. "I really do believe that as good of a ballplayer as he is, he's a much better person. He's very kind, considerate, he cares," Roberts told the AP. "I'm just proud of any fame or glory or award that he receives because he just does it in such a respectful and humble way." Ohtani relishes his privacy and rarely shares details about himself off the field. That's why his February announcement via Instagram that he had wed Mamiko Tanaka, a former basketball player, stunned his new teammates and the rest of the world. The following month, after the Dodgers arrived in South Korea to open the season, he was enveloped in scandal when his longtime interpreter and friend, Ippei Mizuhara, was fired by the Dodgers after being accused of using millions of dollars of Ohtani's money to place bets with an illegal bookmaker. His new teammates rallied around Ohtani, who was found to have no part in the wrongdoing, and publicly it didn't seem to affect him even if he was privately distressed by it. By June, the uproar had subsided. Mizuhara pleaded guilty to federal bank and tax fraud charges and admitted to stealing nearly $17 million from Ohtani. The public got a glimpse of Ohtani's softer side in August, when his dog Decoy delivered a first pitch to his owner on their shared bobblehead night. The Nederlandse Kooikerhondje exchanged an endearing high-five with Ohtani at the plate. As a result, Decoy became a celebrity in his own right, with his breed (pronounced COY-ker-HUND-che) making the list of the most mispronounced words of 2024. He and Ohtani were mentioned during the telecast of last month's National Dog Show, where the small Spaniel-type breed was among the competitors. "The number of the breed has kind of dwindled, so by him gaining a little bit of popularity hopefully that brings up the number of his breed," Ohtani said. "I do feel like we were able to, in a small way, contribute to the popularity of the dog and I'm sure Decoy himself would be happy about that." Ohtani will be looking to top himself next year while eyeing a repeat World Series title. "It's almost like right now you can lock in the Most Valuable Player in the National League award because no one has that ability or talent," Roberts said. "I'm just excited to see what '25 has for Shohei Ohtani." Get local news delivered to your inbox!
Carolina Hurricanes (16-6-1, in the Metropolitan Division) vs. Florida Panthers (14-9-1, in the Atlantic Division) Sunrise, Florida; Saturday, 4 p.m. EST BETMGM SPORTSBOOK LINE: Panthers -123, Hurricanes +103; over/under is 6.5 BOTTOM LINE: The Florida Panthers and the Carolina Hurricanes hit the ice in Eastern Conference action. Florida has gone 7-5-1 at home and 14-9-1 overall. The Panthers have a 3-0-1 record in one-goal games. Carolina has a 7-4-1 record on the road and a 16-6-1 record overall. The Hurricanes are 7-2-0 when they commit fewer penalties than their opponent. Saturday's game is the second meeting between these teams this season. The Panthers won the previous matchup 6-3. TOP PERFORMERS: Sam Bennett has 11 goals and 11 assists for the Panthers. Sam Reinhart has seven goals and four assists over the last 10 games. Jack Roslovic has 12 goals and three assists for the Hurricanes. Seth Jarvis has four goals and six assists over the past 10 games. LAST 10 GAMES: Panthers: 4-6-0, averaging 3.1 goals, 5.6 assists, 4.1 penalties and 10.7 penalty minutes while giving up 2.9 goals per game. Hurricanes: 6-3-1, averaging 3.7 goals, 6.3 assists, 2.7 penalties and 5.6 penalty minutes while giving up 2.8 goals per game. INJURIES: Panthers: None listed. Hurricanes: None listed. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR ), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen [email protected] 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg [email protected] -- Financial Tables Follow – SOURCE Citius Oncology, Inc.
Donald Trump has urged the U.S. Supreme Court to pause a federal TikTok law that would ban the popular social media app or force its sale, with the Republican U.S. president-elect arguing that he should have time after taking office to pursue a "political resolution" to the issue. TikTok and its owner ByteDance are fighting to keep the popular app online in the United States after Congress voted in April to ban it unless the app's Chinese parent company sells it by Jan. 19. They have sought to have the law struck down, and the Supreme Court has agreed to hear the case. But if the court does not rule in ByteDance's favor and no divestment occurs, the app could be effectively banned in the United States on Jan. 19, one day before Trump takes office. "This case presents an unprecedented, novel, and difficult tension between free-speech rights on one side, and foreign policy and national security concerns on the other," Trump said in a filing on Friday. "Such a stay would vitally grant President Trump the opportunity to pursue a political resolution that could obviate the Court's need to decide these constitutionally significant questions," the filing added. Free speech advocates separately told the Supreme Court on Friday that the U.S. law against Chinese-owned TikTok evokes the censorship regimes put in place by the United States' authoritarian enemies. Trump indicated earlier this week that he favored allowing TikTok to keep operating in the United States for at least a little while, saying he had received billions of views on the social media platform during his presidential campaign. The U.S. Justice Department has argued that Chinese control of TikTok poses a continuing threat to national security, a position supported by most U.S. lawmakers. TikTok says the Justice Department has misstated the social media app's ties to China, arguing that its content recommendation engine and user data are stored in the United States on cloud servers operated by Oracle Corp while content moderation decisions that affect U.S. users are made in the United States as well. (Reporting by Kanishka Singh; Editing by Alistair Bell)Coming July 1, Vallejo’s Cal Maritime Academy and San Luis Obispo’s California Polytechnic State University will operate as a single university: Cal Poly. The name change — Cal Maritime Academy will officially be known as “Cal Poly, Solano Campus,” housing the “Cal Poly Maritime Academy” — comes after Thursday’s California State University Board of Trustees vote to approve a CSU Chancellor recommendation to integrate the two schools. The Times-Herald first reported on the story in June when a recommendation was made to integrate the Vallejo university with California Polytechnic State University, San Luis Obispo. The integration would be complete by the start of the 2026-27 academic year. The only degree-granting maritime academy on the West Coast and one of only six state maritime academies in the United States, Cal Maritime has experienced a 31 percent enrollment decline over the last seven years — going from approximately 1,100 students in 2016-17 to just over 750 in 2023-24, according to the CSU statement. There are 81 members of faculty, with 176 staff. The rising employment and operational costs have contributed to the fiscal crisis for Cal Maritime, which has an annul budget of $53 million. Work on the integration process is currently underway. Planning and implementation will take place over the coming months. The first Cal Poly Maritime Academy and Cal Poly, Solano Campus students enrolling as Cal Poly students will take place in fall of 2026. Integration will result in one university (Cal Poly) under one president, President Jeffrey D. Armstrong. After July, a vice president and chief executive officer will lead the Solano campus while a superintendent will be appointed to lead the Cal Poly Maritime Academy. The VP/CEO will report to the president of Cal Poly and serve on the president’s leadership cabinet. The superintendent will report to the VP/CEO. Until July 1, Michael Dumont will continue to serve as interim president of Cal Maritime. Additionally, integration will result in a single administrative structure, one budget and one of each of the appropriate shared governance structures, including faculty/academic senates, one Associated Students, one alumni association and one philanthropic foundation. The integration is considered a permanent solution and Cal Maritime will not be going back to an independent school in the future. The CSU is providing $35 million in one-time funds to support the integration that will be distributed over seven years. It is unclear at this time whether or not jobs will be lost due to the integration. A statement on Thursday by Cal Maritime said, “It is premature to begin analyzing the impact on the Cal Maritime workforce. Analysis will be needed to determine existing capabilities and future requirements. Much of the analysis will depend upon future enrollment numbers.” Workgroups were formed comprising subject matter experts from the CSU Chancellor’s Office, Cal Poly and Cal Maritime across the 23 operational areas identified as most critical to a seamless and timely integration. Those 23 groups have been consolidated into seven functional implementation teams organized under thematic work areas: academics; enrollment; student affairs; advancement, communications and external relations; financial, administrative and human resources; technology; and legal, regulatory and accreditation matters. Informed and guided by Baker Tilly — a firm with extensive national experience in this highly specialized area — the seven FIT teams are now mapping the previously identified critical issues to activities that will form the foundation of an implementation plan. CSU Executive Vice Chancellor and Chief Financial Officer Steve Relyea and Deputy Vice Chancellor of Academic and Student Affairs and Chief Academic Officer Nathan Evans made the recommendation to Chancellor Mildred García during the summer. “The integration of Cal Maritime and Cal Poly will benefit the students, faculty and staff of both institutions, as well as advance the broader mission of the CSU system by enhancing the quality, diversity and sustainability of the CSU’s academic programs and services statewide,” said Relyea and Evans in a CSU statement. “In addition, it will serve industry and workforce needs of the state of California and of the nation while also supporting U.S. economic and national security interests. We are confident in our recommendation.” Garcia was also in favor of the integration. “The recommended integration of Cal Maritime and Cal Poly is an innovative and vitally necessary strategy with benefits that will be felt throughout the CSU, the state of California and our nation,” said García in June. “It provides a long-term solution to Cal Maritime’s untenable fiscal circumstances, preserves its licensure-granting academic programs so key to the maritime industry and our state’s and nation’s economy and security, and leverages academic and operational synergies between the two universities that will benefit California’s diverse students, families and communities for generations.” Numerous options were considered to preserve Cal Maritime’s unique programs while ensuring financial feasibility and sustainability. It was determined that Cal Poly was clearly the best aligned with Cal Maritime for a successful integration because the schools have similar institutions in many fundamental ways, primarily in their academic missions and learning ethos. Both institutions rely upon a hands-on approach and both offer degree programs within high return-on-investment program areas. Clear synergistic opportunities exist in multiple academic programs, perhaps most obviously within the engineering and marine science fields. Both institutions also are involved in national and economic security issues that impact the western U.S., the Pacific Rim and beyond. There is also untapped potential in the ability of the two institutions, if combined, to compete for increased federal, philanthropic and other sources of funding for national security, renewable energy and other programs. Last summer, Dumont began his tenure as interim president at Cal Maritime, taking over for Thomas A. Cropper who announced in November of 2022 that he would retire in August of 2023. The merging comes after recent controversy at Cal Maritime. A Vallejo Times-Herald report in 2021 exposed decades-long claims of sexual assault and sexual harassment, homophobia, transphobia and racism on campus and during training cruises. Cal Maritime students and employees reported accusations of rape, sexual assault and sexual harassment aboard the 500-foot ship to officials at the Vallejo campus between 2019-2022. The merger also comes two months after Dumont announced that the school will be end its longtime affiliation with the National Association of Intercollegiate Athletics and the California Pacific Conference, a result of the association’s recent adoption of its Transgender Participation Policy. The National Association of Intercollegiate Athletics, the governing body for mostly small colleges, announced with a 20-vote in April a policy banning transgender athletes from competing in women’s sports. The organization, which oversees some 83,000 athletes at schools across the country, is believed to be the first college sports organization to take such a step. Since then the school has been recognized on multiple spots on the badge-eligible list of U.S. News and World Report’s list of 2024 Best Colleges. The college was recognized for top performances in academic reputation, cost of attendance and return on investment. The college scored No. 1 for Top Public Schools and ranked No. 2 out of 103 for Regional Colleges-West. Additionally, Cal Maritime was included on Forbes’ list of America’s Top Colleges 2023. Forbes’ annual list showcases 500 of the finest U.S. colleges, ranked using data on student success, return on investment and alumni influence. Although CSU said in a June statement that the challenges the school faces is nothing new, Cal Maritime has implemented several actions to reduce expenses and increase revenues. “Cal Maritime has been part of Vallejo’s rich history and a source of pride for eight decades. Our students, faculty, staff and alumni have played an important role in the history of the state, the region and the nation,” said Dumont during the summer. “An integration with Cal Poly is an amazing opportunity to honor that legacy by preserving one of the nation’s premier maritime academies.”TORONTO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc., (CBOE: ABXX) (OTCQX: ABXXF) (“ Abaxx ” or the “ Company ”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“ Abaxx Singapore ”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “ Abaxx Exchange ” and “ Abaxx Clearing ”), and producer of the SmarterMarketsTM Podcast, today announces that it has filed an early warning report in respect of MineHub Technologies Inc. (“ MineHub ”). On December 27, 2024, pursuant to a share purchase agreement between Abaxx and MineHub dated December 3, 2024 (the “ SPA ”), Abaxx acquired 8,810,000 common shares of MineHub (“ MineHub Shares ”). Prior to the closing of the SPA (the “ Closing ”), Abaxx held 8,333,333 MineHub Shares representing 10.83% of the issued and outstanding MineHub Shares on an undiluted and a partially diluted basis. Immediately after Closing, Abaxx held 17,143,333 MineHub Shares, representing 19.87% of the issued and outstanding MineHub Shares on an undiluted and a partially diluted basis. As a result of the MineHub Shares issued in connection with the SPA, Abaxx’s holdings have changed by more than 2% on a partially diluted basis since the filing of its previous early warning report. The MineHub Shares held by Abaxx are for investment purposes. In accordance with applicable securities laws, Abaxx may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments of MineHub in the open market or otherwise, and reserves the right to dispose of any or all of such securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to such securities, the whole depending on market conditions, the business and prospects of MineHub and other relevant factors. This disclosure is issued pursuant to National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues , which also requires an early warning report to be filed with the applicable securities regulators containing additional information with respect to the foregoing matters. A copy of the early warning report will be filed by Abaxx under MineHub’s profile on SEDAR+ at www.sedarplus.com or may be obtained at Abaxx’s head office address at 110 Young St., Suite 1601, Toronto, Ontario M5C 1T4. The MineHub Shares are listed on the TSX Venture Exchange under the symbol “MHUB”. MineHub is a corporation existing under the laws of British Columbia with its head office at Suite 918 - 1030 West Georgia St., Vancouver, British Columbia, V6E 2Y3, Canada. About Abaxx Technologies Abaxx is building Smarter Markets — markets empowered by better financial technology and market infrastructure to address our biggest challenges, including the energy transition. In addition to developing and deploying financial technologies that make communication, trade, and transactions easier and more secure, Abaxx is an indirect majority-owner of subsidiaries Abaxx Exchange and Abaxx Clearing, recognized by MAS as a “recognised market operator” (RMO) and “approved clearing house” (ACH), respectively. Abaxx Exchange and Abaxx Clearing are a Singapore-based commodity futures exchange and clearinghouse, introducing centrally cleared, physically deliverable commodities futures and derivatives to provide better price discovery and risk management tools for the commodities critical to our transition to a lower-carbon economy. For more information please visit abaxx.tech , abaxx.exchange and smartermarkets.media . Media and investor inquiries: Abaxx Technologies Inc. Investor Relations Team Tel: +1 246 271 0082 E-mail: ir@abaxx.tech Cautionary Statement Regarding Forward-Looking Information This press release includes certain “forward-looking statements” which do not consist of historical facts. Forward-looking statements include estimates and statements that describe Abaxx’s future plans, objectives, or goals, including words to the effect that Abaxx expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “seeking”, “should”, “intend”, “predict”, “potential”, “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, “continue”, “plan” or the negative of these terms and similar expressions. Since forward-looking statements are based on current expectations and assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Abaxx, Abaxx does not provide any assurance that actual results will meet respective management expectations. Risks, uncertainties, assumptions, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information related to Abaxx in this press release includes but is not limited to, Abaxx’s objectives, goals, and future plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions including material estimates and assumptions related to the factors set forth below that, while considered reasonable by Abaxx as at the date of this press release in light of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Such factors impacting forward-looking information include, among others: risks relating to the global economic climate and extreme weather events; dilution; Abaxx’s limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the industry; currency exchange risks; the need for Abaxx to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; the effect of government regulation and compliance on Abaxx and the industry; regulatory risks in Singapore and Canada; the ability to list Abaxx’s securities on stock exchanges in a timely fashion or at all; network security risks; the ability of Abaxx to maintain properly working systems; reliance on key personnel; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; taxation; resource shortages; damage to the Company’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company’s operations, whether true or not; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; the impact of inflation, including global energy cost increases; and volatile securities markets impacting security pricing unrelated to operating performance. In addition, particular factors which could impact future results of the business of Abaxx include but are not limited to: operations in foreign jurisdictions, protection of intellectual property rights, contractual risk, third-party risk; clearinghouse risk, malicious actor risks, third-party software license risk, system failure risk, risk of technological change; dependence of technical infrastructure; changes in the price of commodities, capital market conditions and restriction on labor and international travel and supply chains. Abaxx has also assumed that no significant events occur outside of Abaxx’s normal course of business. Abaxx cautions that the foregoing list of material factors is not exhaustive. In addition, although Abaxx has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. When relying on forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Readers are cautioned that forward-looking statements are not guarantees of future performance. Abaxx has assumed that the material factors referred to in the previous paragraphs will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking statements and information contained in this press release represents the expectations of Abaxx as of the date of this press release and, accordingly, is subject to change after such date. Abaxx undertakes no obligation to update or revise any forward-looking statements and information, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements and information. Cboe Canada does not accept responsibility for the adequacy or accuracy of this press release.